Skip to content
lifestyle.streetregister.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
InnoCare Pharma
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
June 5, 2026
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
June 2, 2026
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
May 28, 2026
InnoCare Announces Approval of Orelabrutinib in Australia
May 27, 2026
2026 ASCO | Pivotal Data of InnoCare’s Novel BCL2 Inhibitor Mesutoclax Released
May 25, 2026
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 24, 2026
←
Previous Page
1
2
3